Savillex, LLC has completed its acquisition of the Life Sciences Fluid Management business of Entegris, Inc., the Eden Prairie, Minnesota-based provider of high-purity fluid handling solutions announced. The acquired business is based in Billerica, Massachusetts.
The portfolio being transferred includes bioprocessing and pharmaceutical manufacturing solutions: Aramus and PE bags, single-use assemblies, and components used in discovery, clinical and commercial manufacturing. Savillex said the addition broadens its life sciences offerings with more high-performance single-use products.
Portfolio and customer support
Savillex is taking on the Life Sciences Fluid Management team and its high-purity fluid management technologies. According to the company, customers can expect a wider range of single-use solutions, additional technical expertise and enhanced capabilities for applications spanning early-stage research through commercial manufacturing. Savillex said the complementary strengths should help customers manage increasingly complex bioprocessing workflows.
CEO Eric Giesing said the acquired business has established a strong reputation in high-purity single-use bioprocessing and that the Aramus line fits with Savillex’s existing Savillex, Containment and Bioprocessing offerings. He said the transaction expands the portfolio and allows the company to serve biopharmaceutical and pharmaceutical customers with a broader range of solutions. Giesing also welcomed the team and said Savillex would continue investing in technologies intended to help customers accelerate development and production of critical therapies.
Chris Bedi, general manager of Fluid Management at Savillex, said the acquisition creates an opportunity to offer a broader set of high-value fluid management solutions to pharmaceutical and biopharmaceutical customers worldwide. He said the Fluid Management portfolio complements Savillex’s existing capabilities and that the combined organization will continue to provide innovative solutions while expanding support across drug development.
The acquired products are intended for use across the drug development continuum, from discovery work and clinical supply to commercial production. By adding these items, Savillex is combining its existing fluid handling business with single-use technologies designed for high-purity bioprocessing and pharmaceutical manufacturing. The company said the addition supports its aim of meeting the evolving needs of manufacturers worldwide.
Transaction details
Savillex said the acquisition advances its strategy of delivering industry-leading solutions for the life sciences market and that it remains committed to innovation, quality and customer partnership. The company did not disclose the terms of the transaction.
EC M&A, based in New York, served as financial advisor to Savillex, and Sidley Austin LLP, based in Chicago, served as legal counsel.